Last reviewed · How we verify
Ganirelix Acetate, Cetrolix Acetate
Ganirelix Acetate, Cetrolix Acetate is a GnRH antagonist Small molecule drug developed by Assaf-Harofeh Medical Center. It is currently FDA-approved for Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF).
Ganirelix and Cetrolix are gonadotropin-releasing hormone (GnRH) antagonists that block GnRH receptors to suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.
Ganirelix and Cetrolix are gonadotropin-releasing hormone (GnRH) antagonists that block GnRH receptors to suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Used for Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF).
At a glance
| Generic name | Ganirelix Acetate, Cetrolix Acetate |
|---|---|
| Sponsor | Assaf-Harofeh Medical Center |
| Drug class | GnRH antagonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
These peptide antagonists competitively bind to GnRH receptors on pituitary gonadotroph cells, rapidly suppressing gonadotropin release without an initial flare effect. This prevents premature LH surge during controlled ovarian hyperstimulation, allowing precise timing of oocyte retrieval in assisted reproductive technology cycles.
Approved indications
- Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF)
Common side effects
- Headache
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions
- Abdominal pain/discomfort
- Nausea
Key clinical trials
- GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst (PHASE4)
- GnRH Antagonist Pre-treatment for the Prevention of Asynchronous Follicular Growth (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ganirelix Acetate, Cetrolix Acetate CI brief — competitive landscape report
- Ganirelix Acetate, Cetrolix Acetate updates RSS · CI watch RSS
- Assaf-Harofeh Medical Center portfolio CI
Frequently asked questions about Ganirelix Acetate, Cetrolix Acetate
What is Ganirelix Acetate, Cetrolix Acetate?
How does Ganirelix Acetate, Cetrolix Acetate work?
What is Ganirelix Acetate, Cetrolix Acetate used for?
Who makes Ganirelix Acetate, Cetrolix Acetate?
What drug class is Ganirelix Acetate, Cetrolix Acetate in?
What development phase is Ganirelix Acetate, Cetrolix Acetate in?
What are the side effects of Ganirelix Acetate, Cetrolix Acetate?
What does Ganirelix Acetate, Cetrolix Acetate target?
Related
- Drug class: All GnRH antagonist drugs
- Target: All drugs targeting GnRH receptor
- Manufacturer: Assaf-Harofeh Medical Center — full pipeline
- Therapeutic area: All drugs in Reproductive Medicine / Fertility
- Indication: Drugs for Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF)
- Compare: Ganirelix Acetate, Cetrolix Acetate vs similar drugs
- Pricing: Ganirelix Acetate, Cetrolix Acetate cost, discount & access